MAIA Biotechnology (MAIA) Fundamental Analysis: Revenue, Earnings & Valuation

1.78 / 10

Underperform

Fundamental rating is Underperform with a 1.8/10 score. Strengths include accounts receivable turnover and interest coverage, but fixed‑asset turnover and income‑tax ratio are weak. Most factor scores are low, indicating concerning financial health and limited upside.

Analysis Checks(6/10)

Revenue-MV

Value-0.28

Score3/3

Weight66.25%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value78.05

Score2/3

Weight3.52%

1M Return0.58%

Inventory turnover ratio

Value47.57

Score3/3

Weight-3.76%

1M Return-0.67%

Accounts receivable turnover ratio

Value25.89

Score2/3

Weight-3.73%

1M Return-0.65%

PB-ROE

Value0.59

Score0/3

Weight27.24%

1M Return3.80%

Income tax / Total profit (%)

Value-5.52

Score0/3

Weight-8.47%

1M Return-1.54%

Fixed assets turnover ratio

Value7899.90

Score1/3

Weight-6.98%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-4.20%

1M Return-0.73%

Cost of sales ratio (%)

Value70.30

Score2/3

Weight-4.13%

1M Return-0.74%

Asset-MV

Value-0.48

Score0/3

Weight34.26%

1M Return4.88%

Is MAIA undervalued or overvalued?

MAIA scores 1.78/10 on fundamentals and holds a Premium valuation at present. Backed by its -745.24% ROE, 0.00% net margin, -3.55 P/E ratio, 33.45 P/B ratio, and 33.33% earnings growth, these metrics solidify its Underperform investment rating.